Berotralstat

Berotralstat (BCX7353) 是一种低毒性，有效，高特异性，第二代，具有口服活性的 plasma kallikrein 抑制剂，用于遗传性血管水肿 (hereditary angioedema，HAE) 的研究。 Berotralstat 通过阻断 plasma kallikrein 释放缓激肽的酶活性来发挥作用，缓激肽是促进与 HAE 发作相关的肿胀和疼痛的主要生物肽。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥4525.00

3620.00

- +
5mg

￥13350.00

10680.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Berotralstat (BCX7353) is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE[1][2].

[1]. Zuraw B, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial [published online ahead of print, 2020 Oct 21]. J Allergy Clin Immunol. 2020;S0091-6749(20)31484-6.
[2]. Manning ME, et al. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies. Allergy Asthma Proc. 2021;42(4):274-282.